Tsukuba, Japan

Hiroyuki Kaizawa

This inventor holds 21 USPTO granted patents and 1 published patent application, plus 5 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Astellas Pharma Gmbh, Imperial Cancer Research Technology, Ltd., Ludwig Institute for Cancer Research Limited. Active years: 2002-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroyuki Kaizawa. Retrieved from https://idiyas.com/inventor/hiroyuki-kaizawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 76.2


 

Average Co-Inventor Count = 9.3

ph-index = 8

Forward Citations = 421(Granted Patents)


Location History:

  • Tsukuba, JP (2002 - 2011)
  • Tokyo, JP (2013 - 2021)

Company Filing History:


Years Active: 2002-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pyridine Derivative
PDE9 Inhibitors
Fused Heteroaryl Derivatives
Imidazopyridine Derivatives
Substituted Amide Compound
Pyrazoloquinoline Compound
Substituted Imidazoquinoxalin
Storage Dysfunction
Bladder Diseases
Urethral Diseases
21 patents (USPTO):Explore Patents

Title: Hiroyuki Kaizawa: Innovator in Pharmaceutical Advancements

Introduction

Hiroyuki Kaizawa, based in Tsukuba, Japan, is a distinguished inventor with an impressive portfolio of 21 patents. His work primarily focuses on pharmaceutical compositions that address critical health issues, demonstrating his commitment to improving patient care and treatment options.

Latest Patents

One of Hiroyuki's noteworthy innovations is a pyridine derivative aimed at treating nocturia. The invention addresses the need for a compound suitable for pharmaceutical applications, specifically targeting the challenges presented by nocturnal voiding. Through extensive research, the inventors, including Hiroyuki, hypothesized that inhibiting placental leucine aminopeptidase (P-LAP) could maintain or increase endogenous arginine vasopressin (AVP) levels, thereby enhancing the antidiuretic effect. Their studies have shown that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives exhibit significant P-LAP inhibitory activity. The results indicated that these compounds can effectively reduce urine production by elevating endogenous AVP levels.

Career Highlights

Hiroyuki has built a robust career within prominent organizations in the pharmaceutical industry. Notable among them is Astellas Pharma GmbH, where he contributed to groundbreaking advancements in drug development. His expertise in medicinal chemistry and his innovative approach have been instrumental in the progression of various therapeutic agents.

Collaborations

Throughout his career, Hiroyuki has had the opportunity to collaborate with notable professionals such as Masahiko Hayakawa and Minoru Okada. Together, they have pooled their knowledge and skills to advance research and develop effective pharmaceutical solutions, reflecting the importance of teamwork in driving innovation.

Conclusion

Hiroyuki Kaizawa stands out as a significant contributor to the field of pharmaceuticals. With his 21 patents, he continues to pave the way for innovations that address pressing health challenges. His persistent efforts and collaborations emphasize the critical role of inventors in advancing medical science and improving health outcomes for patients globally.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…